PTO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A and B/PTO

Sheet

(use as many sheets as necessary)

of

Complete if Known Application Number 10/517,319 Filing Date 07/15/2005 First Named Inventor Philippe Tessler Art Unit 1653 **Examiner Name** 6013-149US MG/pd Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examinar Initizis*	Cite No.1	Document Number Number - Kind Code ² (V known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Whore Refevant Passages or Relevan Figures Appear
1ht.		US 5,731,166	03/24/1998	Geczy Carolyn et al.	
つくて		US 6,103,497	08/15/2000	Cortey Neil et al.	
					*- :
				-	

			- 	\	
			 	 	
			1	· 	
			- 	 	
				1	
				 	
			<u> </u>		

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials No.		Foreign Patent Document Country Code3 - Number4 - Kind Code5 (If known)	Publication Date MM-DD-YYYY	Name of Patentee or . Applicant Of Cited Document	Peges, Columns, Lines Where Relevant Pessages or Relevant Figures Appear	r	
9ht.		EP 0,263,072	04/06/1988	Ciba Geigy Ag			
						目	

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0551-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A and B/PTO Application Number 10/517,319 **INFORMATION DISCLOSURE** Filing Date 07/15/2005 First Named Inventor STATEMENT BY APPLICANT Philippe Tessler Art Unit 1653 (use as many sheets as necessary) **Examiner Name** Attorney Docket Number 6013-149US MG/pd of

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
er Initials"	Cite No.	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(e), volume-issue number(s), publisher, city and/or country where published	T ²
Thi	-	DUNN C J ET AL: "Increased expression of neutrophil MRP8 and MRP14 is associated with vascular adhesion molecule activation and differential leukocyte infiltration in delayed-type hypersensitivity suggesting a proinflammatory role for S100 calcium-binding proteins" Biosis, XP002242712 abstract	
1		YEN TINA ET AL: "Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli", Blood, W.B. Saunders, Philadelphia, VA, US, vol. 90, no. 12, 15 December 1997, pages 4812-4821	
		LAGASSE E ET AL: "Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage" Blood, W.B. Saunders, Philadelphia, VA, US, vol. 79, 1992, pages 1907-1915	
		LACKMANN M.: "Identification of a chemotactic domain of the pro-inflammatory S100 Protein CP-10", Journal of immunology, The Williams and Wilkins Co. Baltimore, US, vol. 150, no 7, April 1, 1993, pages 2981-2991	
		DEVERY JANNINE M ET AL: "Acute inflammatory activity of the S100 protein CP-10: Activation of neutrophils in vivo and in vitro." Journal of immunology, vol. 152, no. 4, 1994, pages 1888-1897	
		RYCKMAN CARLE ET AL: "Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion." Journal of immunology, vol. 170, no. 6, 15 March 2003, pages 3233-3242	
V		ROULEAU PASCAL ET AL: "The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis., Clinical immunology (Orlando), vol. 107, no.1, 20 April 2003, pages 46-54	

		وسنست والمستوال والم
Examiner Signature	Date Considered	10.16.66

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



PTC/SB/088 (07-05)

Approved for use through 07/31/2006. Olds 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1935, no persons are required to respond to a codection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/517,319 INFORMATION DISCLOSURE **Filing Date** July 15, 2005 STATEMENT BY APPLICANT First Named Inventor Philippe A. TESSIER Art Unit 1653 (Use as many sheets as necessary) **Examiner Name** Marsha M. TSAY Attorney Docket Number Sheet 1 6013-149US of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MT,	,	DONATO, Rosario: "Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type" Biochimica et Biophysica Acta 1450 (1999), pages 191-231	
MT.		RAVASI, Timothy et al.: "Probing the S100 protein family through genomic and functional analysis" Genomics 84 (2004), pages 10-22	
		·	

Examiner Signature	70	1 (0)	Date Considered	10,19.06

EXAMINER: Initial if reference considered, whother or not citation is in conformance with MPEP 809. Draw line through citation is not in conformance and not considered. Include copy of this form with next conformance in the applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1,98. The Information is required to obtain or retain a benefit by the public which is to fiel (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: